title: [Clinical practice guidelines from the Andalusian Society of Infectious Diseases (SAEI) for the treatment of tuberculosis].
abstract: The therapeutic scheme for initial pulmonary tuberculosis recommended by the SAEI is as follows: Initial phase, isoniazid, rifampin and pyrazinamide given daily for 2 months. In HIV(+) patients and immigrants from areas with a rate of primary resistance to isoniazid > 4%, ethambutol should be added until susceptibility studies are available. Second phase (continuation phase): rifampin and isoniazid, given daily or intermittently for 4 months in the general population. HIV(+) patients (< or = 200 CD4) and culture-positive patients after 2 months of treatment should receive a 7-month continuation phase. A 6-month regimen is recommended for extrapulmonary tuberculosis, with the exception of tuberculous meningitis, which should be treated for a minimum of 12 months and bone/joint tuberculosis, treated for a minimum of 9 months. Treatment regimens for multidrug resistant tuberculosis are based on expert opinion. These would include a combination of still-useful first-line drugs, injectable agents, and alternative agents, such as quinolones. Patients who present a special risk of transmitting the disease or of non-adherence should be treated with directly observed therapy.
authors.affiliation: Sociedad Andaluza de Enfermedades Infecciosas (SAEI). Andalucía. España. adomin@saludalia.com
authors.forename: Angel
authors.initials: A
authors.lastname: Domínguez-Castellano
authors.forename: Alfonso
authors.initials: A
authors.lastname: Del Arco
authors.forename: Jesús
authors.initials: J
authors.lastname: Canueto-Quintero
authors.forename: Antonio
authors.initials: A
authors.lastname: Rivero-Román
authors.forename: José María
authors.initials: JM
authors.lastname: Kindelán
authors.forename: Ricardo
authors.initials: R
authors.lastname: Creagh
authors.forename: Felipe
authors.initials: F
authors.lastname: Díez-García
mesh_terms: D000328:Adult; D000995:Antitubercular Agents / Q000008:administration & dosage / Q000145:classification / Q000627:therapeutic use*; D002648:Child; D002986:Clinical Trials as Topic; D015897:Comorbidity; D019468:Disease Management; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D004641:Emigration and Immigration; D019317:Evidence-Based Medicine; D005260:Female; D015658:HIV Infections / Q000453:epidemiology; D006801:Humans; D008297:Male; D009928:Organ Specificity; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy; D016879:Salvage Therapy; D016312:Treatment Refusal; D014376:Tuberculosis / Q000188:drug therapy* / Q000453:epidemiology; D018088:Tuberculosis, Multidrug-Resistant / Q000188:drug therapy / Q000453:epidemiology
chemical_list: D000995:Antitubercular Agents